Phase 4 N=150 EVARREST™ Fibrin Sealant Patch Post-Market Study
Hemorrhage · Soft Tissue Bleeding
Primary: Safety Parameter - Incidence of Thromboembolic Events — 2; 7 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=710 A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.
Nausea and Vomiting, Chemotherapy-Induced
Primary: Percentage of Participants Who Achieved a Complete Response in the Overall Phase (0-120 Hours) Following Initiation of the First Cycle of an Oxaliplatin Based Moderately…
N/A N=300 Pivotal Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon
Peripheral Arterial Disease
Primary: Patency at 12 Month Post-procedure — 53; 135 Participants
N/A N=115 Comprehensive HIV Prevention Package for MSM in Southern Africa: Pilot Study (Sibanye Health Project)
HIV
Primary: Retention in the Cohort — 88; 84; 87 Participants
Phase 3 N=735 A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057
Systemic Lupus Erythematosus
Primary: Number of Participants With Adverse Events (AE) — 706; 617; 502; 441 Participants
Phase 4 N=115 Systemic Steroids for Peripheral Nerve Blocks
Osteoarthritis, Hip
Primary: Duration of Sensory Blockade — 18.5; 18.1; 19.6 hours
Phase 3 N=17 Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis
Cystinosis
Primary: Mean White Blood Cell (WBC) Cystine Concentration at Each Visit — 3.1709; 2.2899; 1.8474; 2.3403 nmol 1/2 Cystine/mg protein
Phase 2 N=9 Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
Estrogen Receptor-negative Breast Cancer · HER2-negative Breast Cancer · Progesterone Receptor-negative Breast Cancer
Primary: Count of Participants That Achieve Pathologic Complete Response (PCR) — 3; 3 Participants
Phase 2 N=40 Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
Recurrent Melanoma · Stage III Melanoma · Stage IV Melanoma
Primary: MTD, Defined as One Dose Level Below the Dose That Induced DLT in at Least One Third of Patients at a Dose Level, Graded According to NCI CTCAE Version 3.0 (Phase I) — 2…
N/A N=22 Static Magnetic Therapy for Carpal Tunnel Syndrome
Carpal Tunnel Syndrome
Primary: Change in Boston Carpal Tunnel Questionnaire (BCTQ) Score at 6 Weeks — 48.6; 45.4 units on a scale
N/A N=15 Neural Signatures of Parkinson's Disease
Parkinson's Disease
Primary: Change in Resting State Beta Band Power Over Time — -0.28 regression beta coefficient — p=0.038
N/A N=39 A Comparison of Different Ventilation Strategies in Infants Using the PLMA™
Ventilation
Primary: Mean Values of End-tidal Carbon Dioxide and Tidal Volume Compared Between the Spontaneous Ventilation and Pressure Support Ventilation Groups. — 4.5; 7; 51.8; 49 cc/kg
Phase 3 N=1,974 Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects
Dyslipidemia
Primary: Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score — 0.1206; 0.1134 Z score
N/A N=124 Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients.
Gastrointestinal Hemorrhage · Clostridium Difficile Colitis
Primary: Number of Subjects With GI Bleeding — 1; 1 participants
Phase 2 N=153 Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease
Hyperphosphataemia
Primary: Change in Serum Phosphate Concentration From Baseline (Visit 7, Day 1) to Visit 11 (Day 29) — -0.4; -0.59; -1.29; -1.363 mg/dL — p=0.784